The primary myelofibrosis market size has grown strongly in recent years. It will grow from $0.79 billion in 2024 to $0.84 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. Growth during the historic period was driven by greater awareness of the disease among healthcare providers, expanded use of JAK inhibitors, improved diagnostic and genetic testing capabilities, enhanced access to hematology care, and a rise in clinical research activity.
The primary myelofibrosis market size is expected to see strong growth in the next few years. It will grow to $1.07 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. Contributing factors to future growth include the expansion of innovative treatment pipelines, rising demand for therapies that alter disease progression, increasing incidence among elderly populations, a shift toward combination treatment approaches, and higher levels of investment from pharmaceutical and biotechnology companies. Key emerging trends include progress in precision drug development, the use of next-generation sequencing (NGS) in diagnostics, tech-enabled patient monitoring tools, advancements in multi-drug therapy regimens, and improvements in imaging methods for bone marrow fibrosis.
The growing prevalence of myelofibrosis is anticipated to drive the expansion of the primary myelofibrosis market in the coming years. Myelofibrosis is a rare bone marrow cancer that interferes with the normal production of blood cells, leading to significant scarring in the bone marrow, which in turn causes severe anemia, fatigue, weakness, and an enlarged spleen. This condition is increasingly prevalent due to the aging global population, as it most commonly affects individuals over the age of 60. With life expectancy on the rise, the number of diagnosed cases continues to grow. This increase in prevalence supports advancements in primary myelofibrosis management by promoting research, encouraging early diagnosis, expanding treatment options, and refining clinical guidelines and care strategies. For example, in November 2024, the National Institute for Health and Care Excellence, a UK-based independent executive non-departmental public body, reported that myelofibrosis has a prevalence of 3.2 per 100,000 people in the UK and an incidence rate of 0.6 per 100,000. As a result, the increasing number of cases is contributing to the growth of the primary myelofibrosis market.
Key players in the primary myelofibrosis market are emphasizing the development of innovative treatments such as Janus kinase 2 (JAK2) inhibiting tablets to better manage symptoms and slow disease progression. These oral medications work by blocking the JAK2 enzyme, which is involved in abnormal signaling pathways that result in excessive blood cell production in primary myelofibrosis. JAK2 inhibitors help reduce spleen size, relieve fatigue and bone pain, and slow disease progression. For instance, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a pharmaceutical and biotechnology company based in South Korea, introduced Omjjara (momelotinib), a new treatment for myelofibrosis. Approved by South Korea’s Ministry of Food and Drug Safety, Omjjara is designed for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who suffer from moderate to severe anemia. This oral therapy targets JAK1, JAK2, and activin A receptor type 1 (ACVR1), effectively treating symptoms such as anemia, splenomegaly, and fatigue. Clinical trial results showed significant improvements in these areas compared to existing treatments, supporting the drug’s approval.
In June 2022, GSK plc, a UK-based pharmaceutical and biotechnology firm, completed the acquisition of Sierra Oncology, Inc. for approximately $1.9 billion. This move was intended to strengthen GSK’s oncology pipeline, particularly in the area of hematologic cancers. Sierra Oncology, Inc. is a U.S.-based biopharmaceutical company focused on the development of therapies for primary myelofibrosis.
Major players in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.
North America was the largest region in the primary myelofibrosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in primary myelofibrosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the primary myelofibrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Primary myelofibrosis (PMF) is a rare and chronic bone marrow condition marked by the excessive development of fibrous scar tissue (fibrosis) within the bone marrow. This fibrosis interferes with the normal production of blood cells, resulting in symptoms such as anemia, fatigue, weakness, and an enlarged spleen (splenomegaly). PMF falls under the category of myeloproliferative neoplasms (MPNs) and can also lead to issues like night sweats, unintended weight loss, and bone discomfort.
The major types of primary myelofibrosis include spinocerebellar primary myelofibrosis, primary myelofibrosis-telangiectasia, episodic primary myelofibrosis, and other less common forms. Services provided encompass both diagnosis and treatment, while medication options are offered in multiple dosage forms, including solids, liquids, and other formulations, to cater to various patient needs. This condition can affect individuals of all age groups - children, adults, and the elderly - and is managed in various healthcare environments such as hospitals, clinics, and other care facilities.
The primary myelofibrosis market research report is one of a series of new reports that provides primary myelofibrosis market statistics, including the primary myelofibrosis industry global market size, regional shares, competitors with the primary myelofibrosis market share, detailed primary myelofibrosis market segments, market trends, and opportunities, and any further data you may need to thrive in the primary myelofibrosis industry. These primary myelofibrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The primary myelofibrosis market consists of revenues earned by entities by providing services such as diagnosis services, medical consultations, treatment services, monitoring and follow-up and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary myelofibrosis (PMF) market also includes sales of products including ruxolitinib (Jakafi or Jakavi), erythropoiesis-stimulating agents (ESAs), hydroxyurea, bone marrow or stem cell transplant kits and iron supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The primary myelofibrosis market size is expected to see strong growth in the next few years. It will grow to $1.07 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. Contributing factors to future growth include the expansion of innovative treatment pipelines, rising demand for therapies that alter disease progression, increasing incidence among elderly populations, a shift toward combination treatment approaches, and higher levels of investment from pharmaceutical and biotechnology companies. Key emerging trends include progress in precision drug development, the use of next-generation sequencing (NGS) in diagnostics, tech-enabled patient monitoring tools, advancements in multi-drug therapy regimens, and improvements in imaging methods for bone marrow fibrosis.
The growing prevalence of myelofibrosis is anticipated to drive the expansion of the primary myelofibrosis market in the coming years. Myelofibrosis is a rare bone marrow cancer that interferes with the normal production of blood cells, leading to significant scarring in the bone marrow, which in turn causes severe anemia, fatigue, weakness, and an enlarged spleen. This condition is increasingly prevalent due to the aging global population, as it most commonly affects individuals over the age of 60. With life expectancy on the rise, the number of diagnosed cases continues to grow. This increase in prevalence supports advancements in primary myelofibrosis management by promoting research, encouraging early diagnosis, expanding treatment options, and refining clinical guidelines and care strategies. For example, in November 2024, the National Institute for Health and Care Excellence, a UK-based independent executive non-departmental public body, reported that myelofibrosis has a prevalence of 3.2 per 100,000 people in the UK and an incidence rate of 0.6 per 100,000. As a result, the increasing number of cases is contributing to the growth of the primary myelofibrosis market.
Key players in the primary myelofibrosis market are emphasizing the development of innovative treatments such as Janus kinase 2 (JAK2) inhibiting tablets to better manage symptoms and slow disease progression. These oral medications work by blocking the JAK2 enzyme, which is involved in abnormal signaling pathways that result in excessive blood cell production in primary myelofibrosis. JAK2 inhibitors help reduce spleen size, relieve fatigue and bone pain, and slow disease progression. For instance, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a pharmaceutical and biotechnology company based in South Korea, introduced Omjjara (momelotinib), a new treatment for myelofibrosis. Approved by South Korea’s Ministry of Food and Drug Safety, Omjjara is designed for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who suffer from moderate to severe anemia. This oral therapy targets JAK1, JAK2, and activin A receptor type 1 (ACVR1), effectively treating symptoms such as anemia, splenomegaly, and fatigue. Clinical trial results showed significant improvements in these areas compared to existing treatments, supporting the drug’s approval.
In June 2022, GSK plc, a UK-based pharmaceutical and biotechnology firm, completed the acquisition of Sierra Oncology, Inc. for approximately $1.9 billion. This move was intended to strengthen GSK’s oncology pipeline, particularly in the area of hematologic cancers. Sierra Oncology, Inc. is a U.S.-based biopharmaceutical company focused on the development of therapies for primary myelofibrosis.
Major players in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.
North America was the largest region in the primary myelofibrosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in primary myelofibrosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the primary myelofibrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Primary myelofibrosis (PMF) is a rare and chronic bone marrow condition marked by the excessive development of fibrous scar tissue (fibrosis) within the bone marrow. This fibrosis interferes with the normal production of blood cells, resulting in symptoms such as anemia, fatigue, weakness, and an enlarged spleen (splenomegaly). PMF falls under the category of myeloproliferative neoplasms (MPNs) and can also lead to issues like night sweats, unintended weight loss, and bone discomfort.
The major types of primary myelofibrosis include spinocerebellar primary myelofibrosis, primary myelofibrosis-telangiectasia, episodic primary myelofibrosis, and other less common forms. Services provided encompass both diagnosis and treatment, while medication options are offered in multiple dosage forms, including solids, liquids, and other formulations, to cater to various patient needs. This condition can affect individuals of all age groups - children, adults, and the elderly - and is managed in various healthcare environments such as hospitals, clinics, and other care facilities.
The primary myelofibrosis market research report is one of a series of new reports that provides primary myelofibrosis market statistics, including the primary myelofibrosis industry global market size, regional shares, competitors with the primary myelofibrosis market share, detailed primary myelofibrosis market segments, market trends, and opportunities, and any further data you may need to thrive in the primary myelofibrosis industry. These primary myelofibrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The primary myelofibrosis market consists of revenues earned by entities by providing services such as diagnosis services, medical consultations, treatment services, monitoring and follow-up and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary myelofibrosis (PMF) market also includes sales of products including ruxolitinib (Jakafi or Jakavi), erythropoiesis-stimulating agents (ESAs), hydroxyurea, bone marrow or stem cell transplant kits and iron supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Primary Myelofibrosis Market Characteristics3. Primary Myelofibrosis Market Trends And Strategies4. Primary Myelofibrosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Primary Myelofibrosis Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Primary Myelofibrosis Market34. Recent Developments In The Primary Myelofibrosis Market
5. Global Primary Myelofibrosis Growth Analysis And Strategic Analysis Framework
6. Primary Myelofibrosis Market Segmentation
7. Primary Myelofibrosis Market Regional And Country Analysis
8. Asia-Pacific Primary Myelofibrosis Market
9. China Primary Myelofibrosis Market
10. India Primary Myelofibrosis Market
11. Japan Primary Myelofibrosis Market
12. Australia Primary Myelofibrosis Market
13. Indonesia Primary Myelofibrosis Market
14. South Korea Primary Myelofibrosis Market
15. Western Europe Primary Myelofibrosis Market
16. UK Primary Myelofibrosis Market
17. Germany Primary Myelofibrosis Market
18. France Primary Myelofibrosis Market
19. Italy Primary Myelofibrosis Market
20. Spain Primary Myelofibrosis Market
21. Eastern Europe Primary Myelofibrosis Market
22. Russia Primary Myelofibrosis Market
23. North America Primary Myelofibrosis Market
24. USA Primary Myelofibrosis Market
25. Canada Primary Myelofibrosis Market
26. South America Primary Myelofibrosis Market
27. Brazil Primary Myelofibrosis Market
28. Middle East Primary Myelofibrosis Market
29. Africa Primary Myelofibrosis Market
30. Primary Myelofibrosis Market Competitive Landscape And Company Profiles
31. Primary Myelofibrosis Market Other Major And Innovative Companies
35. Primary Myelofibrosis Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Primary Myelofibrosis Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on primary myelofibrosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for primary myelofibrosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary myelofibrosis market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Spinocerebellar Primary Myelofibrosiss; Primary Myelofibrosis-Telangiectasia; Episodic Primary Myelofibrosis; Other Types2) By Services: Treatment; Diagnosis
3) By Dosage Forms: Solid; Liquids; Other Dosage Forms
4) By Age: Adult; Child; Geriatric
5) By End User: Hospitals; Clinics; Other End Users
Subsegments:
1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis; Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis; Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis; Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis; Ocular Telangiectasia-Associated Myelofibrosis
3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes; Periodic Cytopenia With Fibrosis Flare; Cyclical Myelofibrosis In Autoimmune Disorders
4) By Other Types: Familial Primary Myelofibrosis; Idiopathic Myelofibrosis; Therapy-Related Primary Myelofibrosis; Juvenile Primary Myelofibrosis
Key Companies Profiled: Merck & Co. Inc.; AbbVie Inc.; Bristol-Myers Squibb Company; Sumitomo Pharma Oncology Inc.; Incyte Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Merck & Co. Inc.
- AbbVie Inc.
- Bristol-Myers Squibb Company
- Sumitomo Pharma Oncology Inc.
- Incyte Corporation
- Nippon Shinyaku Co. Ltd.
- MorphoSys AG
- Keros Therapeutics Inc.
- Geron Corporation
- Lynk Pharmaceuticals Co. Ltd.
- Pharmaxis Ltd
- Kartos Therapeutics Inc.
- Disc Medicine Inc.
- Galecto Inc.
- Cellenkos Inc.
- Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
- Taiga Biotechnologies Inc.
- Suzhou Zelgen Biopharmaceuticals Co. Ltd.
- Telios Pharma Inc.
- Samus Therapeutics Inc.
- Jacobio Pharmaceuticals Co. Ltd.
